UPXI:NASDAQUpexi, Inc. Analysis
Data as of 2026-06-20 - not real-time
$0.91
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Upexi, Inc. (UPXI) is trading at $0.91, well below its 20‑day SMA of 1.06 and 50‑day SMA of 1.23, indicating a pronounced bearish price bias. The RSI of 38 suggests limited upside momentum, while the MACD histogram is negative, reinforcing a bearish technical stance. Volatility is extreme at nearly 97% over the past 30 days and the computed beta of 4.26 points to outsized market swings.
Fundamentally, the company reports a 44% revenue growth year‑over‑year, yet operating margins are a disastrous -23.4% and EBITDA is deeply negative. Cash reserves of only $3.5 M are dwarfed by debt exceeding $242 M, and free cash flow is a massive negative, while book value per share sits at -$0.78. The PE ratio of 1.7 looks cheap against an industry average of 16.6, but earnings are essentially zero and forward PE is negative, making valuation metrics misleading. Combined with high regulatory exposure in cannabis and crypto, the stock presents a high‑risk profile despite a theoretical upside of over 450%.
Fundamentally, the company reports a 44% revenue growth year‑over‑year, yet operating margins are a disastrous -23.4% and EBITDA is deeply negative. Cash reserves of only $3.5 M are dwarfed by debt exceeding $242 M, and free cash flow is a massive negative, while book value per share sits at -$0.78. The PE ratio of 1.7 looks cheap against an industry average of 16.6, but earnings are essentially zero and forward PE is negative, making valuation metrics misleading. Combined with high regulatory exposure in cannabis and crypto, the stock presents a high‑risk profile despite a theoretical upside of over 450%.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below all major moving averages and bearish MACD
- Extreme short‑term volatility and beta
- Negative operating cash flow and free cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Revenue growth of 44% suggests top‑line potential
- Continued negative margins and high debt constrain profitability
- Potential catalyst if restructuring or new product lines improve cash generation
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Sustained negative earnings and zero ROE
- Heavy debt load relative to cash and market cap
- Regulatory headwinds in cannabis, crypto and supplement categories
Key Metrics & Analysis
Financial Health
Revenue Growth44.20%
P/E Ratio1.7
ROA-126.53%
P/B Ratio-1.2
Op. Cash Flow$-21524226
Free Cash Flow$-229092160
Industry P/E16.7
Technical Analysis
TrendBearish
RSI38.1
Support$0.85
Resistance$1.42
MA 20$1.06
MA 50$1.23
MA 200$2.55
MACDBearish
VolumeStable
Fear & Greed Index91.46
Valuation
Target Price$5.00
Upside/Downside450.90%
GradeOvervalued
TypeValue
Risk Assessment
Beta4.26
Volatility97.36%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.